Philadelphia, PANCT05995535Now EnrollingIRB Ready

Opioid Withdrawal Clinical Trial in Philadelphia, PA

Access cutting-edge opioid withdrawal treatment through this phase 2 clinical trial at a research site in Philadelphia. Study-provided care at no cost to qualified participants.

Sponsored by University of Pennsylvania

Quick Self-Assessment

See if you qualify for this Philadelphia location

Preparing your pre-screening questions…

Expert Care in Philadelphia

Access opioid withdrawal specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related opioid withdrawal treatment provided free

Apply for This Philadelphia Location

Check if you qualify for this opioid withdrawal clinical trial in Philadelphia, PA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Philadelphia

    Convenient for PA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Philadelphia site if eligible
  4. 4Begin participation

About This Opioid Withdrawal Study in Philadelphia

A placebo-controlled trial in which male and female outpatients with an opioid use disorder who express interest in extended-release injectable naltrexone (XR-NTX) are randomized 1:1 to lofexidine/pregabalin or lofexidine/pregabalin placebo for withdrawal management and offered XR-NTX if after completing withdrawal.

Sponsor: University of Pennsylvania

Who Can Participate

Inclusion Criteria

Male and/or female subjects ≥ 18 years of age
Meet DSM-5 criteria for an Opioid Use Disorder with physiologic features. Have met 2 or more of the 11 criteria for an OUD including tolerance and withdrawal within the last 12 months
Interested in opioid antagonist treatment
Used opioids in 20 or more of the last 30 days
A stable address in the local area; not planning to move in the next 60 days.
Have documents for ID check
Absence of medical or psychiatric conditions that are likely to interfere with study participation
Has 12 lead ECG demonstrating a QTc ≤450 msec and a QRS ≤120 msec. Site PI has final determination for study inclusion if readings exceed these limits. The PENN cardiologists and medical monitor are available for consultation when needed
Negative pregnancy test and using adequate contraception if of childbearing potential.

Exclusion Criteria

Current psychotic disorder (bipolar I, schizophrenia, major depression that is not in remission
Alcohol, benzodiazepine, or other sedative use disorder with physiological features that require medication for detoxification
Allergy or other serious adverse event due to treatment with pregabalin, XR-NTX, or lofexidine
Pending incarceration or plans to leave the immediate area in the next 30 days
Homicidal or otherwise behaviorally disturbed requiring immediate attention
High risk for suicide as determined by answering 'yes' to questions 4 and/or 5 on C-SSRS
Blood pressure \<90 mm Hg (systolic) or \<60 mm Hg (diastolic). If value out of normal range, the investigator and study Clinician will decide subject inclusion/exclusion on case-by-case basis
Heart rate and/or pulse\<50 bpm at screening-sitting
An Estimated Glomerular Filtration Rate eGFR\<70 mL/min/1.73m2
A History of, or current Seizure disorder (excluding childhood febrile seizures)
Inability to read and/or understand English. For example, unable to understand the informed consent as demonstrated by failing to answer 9/10 questions correctly on the quiz
12\. Pregnant or breastfeeding
13\. Currently taking sympathomimetic drugs, or a thiazolidinedione antidiabetic
ALT and/or AST \>4X upper limit of normal
A Child-Pugh score \>7
Currently receiving opioids for pain management
In a treatment study where medication was administered in the last 30 days
Currently using medications that are known to be strong or moderate inhibitors of CYP2D6 such as fluoxetine, paroxetine, mirabegron, bupropion, quinidine, terbinafine, cimetidine, cinacalcet, duloxetine, or fluvoxamine
In a methadone maintenance or buprenorphine treatment program within the last 30 days

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Philadelphia?

Yes, this clinical trial (NCT05995535) has an active research site in Philadelphia, PA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Opioid Withdrawal Treatment Options in Philadelphia, PA

If you're searching for opioid withdrawal treatment options in Philadelphia, PA, this clinical trial (NCT05995535) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Philadelphia research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced opioid withdrawal specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all opioid withdrawal clinical trials near you to find additional studies recruiting in your area.

More Huntingtons Disease Trials in Philadelphia, PA

See all huntingtons disease clinical trials recruiting in Philadelphia — not just this study.

Browse Huntingtons Disease Trials in Philadelphia →

Browse More Trials by Condition

Huntingtons Disease TrialsRheumatoid Arthritis TrialsOsteogenesis Imperfecta TrialsAll Conditions →

Ready to Join in Philadelphia?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Philadelphia, PA